Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice

Chen,Li-Na; Lyu,Juan; Yang,Xue-Fei; Ji,Wen-Jun; Yuan,Bing-Xiang; Chen,Ming-Xia; Ma,Xin; Wang,Bing

doi:10.3892/ijmm.2013.1453

Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice

Authors:
- Li-Na Chen
- Juan Lyu
- Xue-Fei Yang
- Wen-Jun Ji
- Bing-Xiang Yuan
- Ming-Xia Chen
- Xin Ma
- Bing Wang
View Affiliations

Affiliations: Department of Pharmacology, College of Medicine, Xi'an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China, Center of Electron Microscopy, College of Medicine, Xi'an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China
Published online on: July 19, 2013 https://doi.org/10.3892/ijmm.2013.1453
Pages: 892-900

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liraglutide, a long-lasting glucagon‑like peptide‑1 analogue, has been used for the treatment of patients with type 2 diabetes mellitus since 2009. In this study, we investigated the anti-diabetic effects and mechanisms of action of liraglutide in a spontaneous diabetic animal model, using KK/Upj-Ay/J (KKAy) mice. The KKAy mice were divided into 2 groups, the liraglutide group (mice were treated with 250 µg/kg/day liraglutide) and the model group (treated with an equivalent amount of normal saline). C57BL/6J mice were used as the controls (treated with an equivalent amount of normal saline). The treatment period lasted 6 weeks. During this treatment period, fasting blood glucose (FBG) levels and the body weight of the mice were measured on a weekly basis. Our results revealed that liraglutide significantly decreased FBG levels, the area under the curve following a oral glucose tolerance test and insulin tolerance test, increased serum insulin levels, reduced homeostasis model assessment of insulin resistance and increased the insulin sensitivity index. Furthermore, liraglutide ameliorated glycometabolism dysfunction by increasing glycolysis via hexokinase and glycogenesis via pyruvate kinase activation. An ultrastructural examination of the pancreas revealed that liraglutide improved the damaged state of islet β cells and increased the number of insulin secretory granules. The real-time PCR results revealed that the gene expression of glucose transporter 4 (GLUT4) increased following treatment with liraglutide. Liraglutide also upregulated the protein expression of GLUT4 in liver tissue and skeletal muscle. Our results suggest that liraglutide ameliorates glycometabolism and insulin resistance in diabetic KKAy mice by stimulating insulin secretion, increasing glycogenesis and glycolysis and upregulating the expression of GLUT4.

View Figures

View References

1	Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004.PubMed/NCBI
2	Geraldes P and King GL: Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 106:1319–1331. 2010. View Article : Google Scholar : PubMed/NCBI
3	Abdin AA, Baalash AA and Hamooda HE: Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications. 24:168–178. 2010. View Article : Google Scholar : PubMed/NCBI
4	Hayden MR and Sowers JR: Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens. 2:239–266. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li L, Miao Z, Liu R, Yang M, Liu H and Yang G: Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med. 17:1168–1178. 2011.PubMed/NCBI
6	Mundil D, Cameron-Vendrig A and Husain M: GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 9:95–108. 2012. View Article : Google Scholar : PubMed/NCBI
7	Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T and Ito S: The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 59:889–894. 2012. View Article : Google Scholar
8	Hunter K and Hölscher C: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13:332012. View Article : Google Scholar : PubMed/NCBI
9	Kesavadev J, Shankar A, Krishnan G and Jothydev S: Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med. 5:317–322. 2012. View Article : Google Scholar : PubMed/NCBI
10	Fujishima Y, Maeda N, Inoue K, et al: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 11:1072012. View Article : Google Scholar : PubMed/NCBI
11	Fukushima T, Arai T, Ariga-Nedachi M, et al: Insulin receptor substrates form high-molecular-mass complexes that modulate their availability to insulin/insulin-like growth factor-I receptor tyrosine kinases. Biochem Biophys Res Commun. 404:767–773. 2011. View Article : Google Scholar
12	Zhu Y, Pereira RO, O’Neill BT, et al: Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. Mol Endocrinol. 27:172–184. 2013. View Article : Google Scholar : PubMed/NCBI
13	Chen S, Wasserman DH, MacKintosh C and Sakamoto K: Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab. 13:68–79. 2011. View Article : Google Scholar
14	Munkonda MN, Lapointe M, Miegueu P, et al: Recombinant acylation stimulating protein administration to C3^−/− mice increases insulin resistance via adipocyte inflammatory mechanisms. PLoS One. 7:e468832012. View Article : Google Scholar : PubMed/NCBI
15	Wei X, Wang D, Yang Y, et al: Cyanidin-3-O-β-glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity. J Sci Food Agric. 91:1006–1013. 2011.
16	Li PP, Shan S, Chen YT, et al: The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol. 148:610–618. 2006. View Article : Google Scholar : PubMed/NCBI
17	Drucker DJ: The biology of incretin hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
18	Porter DW, Kerr BD, Flatt PR, Holscher C and Gault VA: Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab. 12:891–899. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gault VA, Kerr BD, Harriott P and Flatt PR: Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci (Lond). 121:107–117. 2011. View Article : Google Scholar
20	Shimoda M, Kanda Y, Hamamoto S, et al: The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 54:1098–1108. 2011. View Article : Google Scholar
21	Magnoni LJ, Vraskou Y, Palstra AP and Planas JV: AMP-activated protein kinase plays an important evolutionary conserved role in the regulation of glucose metabolism in fish skeletal muscle cells. PLoS One. 7:e312192012. View Article : Google Scholar
22	Oosterveer MH, Mataki C, Yamamoto H, et al: LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J Clin Invest. 122:2817–2826. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ros S, García-Rocha M, Calbó J and Guinovart JJ: Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in rats. Diabetologia. 54:2639–2648. 2011. View Article : Google Scholar
24	John S, Weiss JN and Ribalet B: Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS One. 6:e176742011. View Article : Google Scholar : PubMed/NCBI
25	Sun L, Shukair S, Naik TJ, Moazed F and Ardehali H: Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol. 28:1007–1017. 2008. View Article : Google Scholar : PubMed/NCBI
26	Holyoak T, Zhang B, Deng J, Tang Q, Prasannan CB and Fenton AW: Energetic coupling between an oxidizable cysteine and the phosphorylatable N-terminus of human liver pyruvate kinase. Biochemistry. 52:466–476. 2013. View Article : Google Scholar : PubMed/NCBI
27	Cortés-Cros M, Hemmerlin C, Ferretti S, et al: M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA. 110:489–494. 2013.PubMed/NCBI
28	Sun Q, Chen X, Ma J, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 108:4129–4134. 2011. View Article : Google Scholar : PubMed/NCBI
29	Ye J, Mancuso A, Tong X, et al: Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 109:6904–6909. 2012. View Article : Google Scholar : PubMed/NCBI
30	Shirakawa J, Tanami R, Togashi Y, et al: Effects of liraglutide on beta-cell-specific glucokinase-deficient neonatal mice. Endocrinology. 153:3066–3075. 2012. View Article : Google Scholar : PubMed/NCBI
31	Janghorbani M and Amini M: Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan, Iran. Endokrynol Pol. 63:372–380. 2012.
32	Ohshima K, Mogi M, Jing F, et al: Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One. 7:e483872012.PubMed/NCBI
33	Rosengren AH, Braun M, Mahdi T, et al: Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes. 61:1726–1733. 2012.
34	Tersey SA, Nishiki Y, Templin AT, et al: Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes. 61:818–827. 2012.
35	Emamaullee JA, Merani S, Toso C, et al: Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology. 150:2145–2152. 2009. View Article : Google Scholar : PubMed/NCBI
36	Sturis J, Gotfredsen CF, Rømer J, et al: GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 140:123–132. 2003. View Article : Google Scholar : PubMed/NCBI
37	Knudsen LB: Liraglutide: the therapeutic promise from animal models. Int J Clin Pract. 167:4–11. 2010. View Article : Google Scholar : PubMed/NCBI
38	Kawamori R: Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension. Hypertens Res. 19(Suppl 1): S61–S64. 1996. View Article : Google Scholar : PubMed/NCBI
39	Tomimoto S, Ojika T, Shintani N, et al: Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. J Pharmacol Sci. 107:41–48. 2008. View Article : Google Scholar : PubMed/NCBI
40	Taniguchi CM, Emanuelli B and Kahn CR: Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 7:85–96. 2006. View Article : Google Scholar : PubMed/NCBI
41	Inokuchi J: Membrane microdomains and insulin resistance. Febs Lett. 584:1864–1871. 2010. View Article : Google Scholar : PubMed/NCBI
42	Chang YC and Chuang LM: The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res. 2:316–331. 2010.PubMed/NCBI
43	Muniyappa R, Montagnani M, Koh KK and Quon MJ: Cardiovascular actions of insulin. Endocr Rev. 28:463–491. 2007. View Article : Google Scholar
44	Lee JO, Song YH, Kim MW, et al: A sub-1-volt nanoelectromechanical switching device. Nat Nanotechnol. 8:36–40. 2013. View Article : Google Scholar : PubMed/NCBI
45	Giannocco G, Oliveira KC, Crajoinas RO, et al: Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol. 698:74–86. 2013. View Article : Google Scholar
46	Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C and Lorenzo M: Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 57:3211–3221. 2008. View Article : Google Scholar : PubMed/NCBI
47	Zhang WY, Lee JJ, Kim IS, Kim Y, Park JS and Myung CS: 7-O-methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro. Biol Pharm Bull. 33:1494–1499. 2010. View Article : Google Scholar : PubMed/NCBI